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Abstract 
Purpose: To explore the plasma pharmacokinetics and heart distribution of Z-GP-EPI, a low cardiotoxic 
prodrug of epirubicin (EPI). 
Methods: The drugs were administered to 20 rats (11. 22, 44 µmol/kg) by intravenous injection and 70 
mice (30 µmol/kg) by tail intravenous injection. The profiles of Z-GP-EPI and EPI in rat plasma or mice 
heart were determined by high performance liquid chromatography (HPLC) method, which employed 
the Octadecylsilyl (ODS) column with a mobile phase of acetonitrile : 0.1 % trifluoroacetic-water (42:58, 
v/v) at a flow rate of 1.0 mL/min and an ultraviolet (UV) detector at a wavelength of 495 nm. 
Pharmacokinetics parameters were calculated using a pharmacokinetic software. 
Results: Relative standard deviation (RSD) of intra- and inter-day precision values was < 15 % in each 
case while method accuracy with recovery was between 85 and 110 % for plasma and heart samples. 
After administration of 22 umol/kg Z-GP-EPI or EPI, terminal elimination half-life (t1/2) of Z-GP-EPI 
(1.41 h) was smaller than that of EPI (12.24 h). Furthermore, the concentration of Z-GP-EPI in heart 
rapidly decreased from 17.3 µg/g (0.05 h) to undetectable levels (2 h) while EPI changed from 14.3 µg/g 
(0.05 h) to 9.5 µg/g (2 h). 
Conclusion: The HPLC method established in this study is a feasible approach to detecting Z-GP-EPI 
and EPI in plasma and heart tissue. In addition, Z-GP-EPI is eliminated more rapidly from plasma and 
heart tissue than EPI, which probably contributes to the low cardiotoxicity of Z-GP-EPI.  
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EPI possesses broad-spectrum antineoplastic 
activity [1]. However, the cardio- toxicity 
associated with EPI is cumulative and dose-
limiting, thus hampering its use in the clinic [2]. 
There are considerable efforts to improve the 
selectivity of anthracycline antibiotics and reduce 
their toxicity using nontoxic prodrugs. Such 
prodrugs are preferentially converted into active 
anticancer agents at the tumor site, where drug-
converting enzymes are expressed at 
significantly higher levels than in normal tissues 
[3-6]. Fibroblast activation protein α (FAPα), a 
serine protease [7], is expressed in over 90 % of 
the stroma of malignant epithelial tumors, but not 
in normal tissues [8-10].  
 
Given this, we have designed an EPI prodrug 
using the FAP-specific dipeptides glutamine (Z), 
glycine (G), and proline (P), and named it Z-GP-
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EPI. In previous studies we have demonstrated 
that Z-GP-EPI could show similar inhibition 
activity to the growth of tumor in tumor-bearing 
mice model compared with EPI. Meanwhile, it 
could reduce the myocardial toxicity, which was 
the main adverse side effect of EPI, and didn’t 
show obvious toxicity to other tissues. In 
addition, it is generally believed that the 
pharmacokinetic properties of a drug are closely 
linked to its efficacy and toxicity [11-14].  
 
Therefore, the objective of this study was to 
explore the plasma pharmacokinetics and heart 
distribution of Z-GP-EPI and compare them with 






Male, specific pathogen-free (SPF) Sprague-
Dawley rats (weighing 250 ± 50 g) and female 
SPF Bal b/c mice (20 ± 2 g) were purchased 
from Medical Experimental Animal Center of 
Guangdong, China. Animal production license 
NO. SCXK (Yue) 2008 - 0002. All the animals 
were housed in an air-conditioned animal quarter 
at a temperature of 25 ± 2 °C and a relative 
humidity of 75 ± 5 %, and kept on 12 h light/12 h 
dark cycle with free access to food. Before the 
experiment, the animals were fasted overnight 
for 12 h and provided water ad libitum. All animal 
experiments were approved by the ethical 
committee of Institute of Laboratory Animal 
Science, Jinan University (License no. SYXK 
(Yue) 2012 - 0117). The animals were handled 
according to standard protocols for the use of 
laboratory animals [15]. 
 
Chemicals and reagents  
 
The preparation of Z-GP-EPI (purity > 99.0 %) 
was accomplished by the College of Pharmacy, 
SunYat-sen University (Guangzhou, China). EPI 
hydrochloride (EPI - HCl) was purchased from 
Hisun Pharmaceutical (purity > 98 %, Zhejiang, 
China). Daunorubicin (DNR; purity > 91.0 %), 
used as the internal standard in the study, was 
provided by the National Institute for Food and 
Drug Control, China. High-performance liquid 
chromatography (HPLC) - grade methanol and 
acetonitrile were provided by Jiangsu Hanbon 
(Jiangsu, China). HPLC-grade trifluoroacetic acid 
was purchased from Guangzhou Dongzheng 
Chemical Glass Instrument (Guangdong, China). 
All other chemicals and reagents at the highest 
grade available were obtained from Guangzhou 
Dongzheng Chemical Glass Instrument 
(Guangdong, China). Distilled water was 
produced in the Laboratory of Pharmacy.  
Chromatography  
 
The chromatographic analysis was performed by 
a 1260 Agilent chromatographic system (USA) 
with UV detector. The detection wavelength was 
495 nm. Ultimate XB-C18 (4.6 × 250 mm, 5 μm, 
Welch materials) was used as analytical column 
with elution mobile phase was acetonitrile: 0.1 % 
trifluoroacetic-water (42:58, v/v) at a flow rate of 
1.0 mL/min, column temperature 25 °C. 
 
Pretreatment of plasma samples and heart 
tissues  
 
A plasma sample (200 μL) was mixed with 20 μL 
of DNR (5 µg/mL for EPI analyses and 8 µg/mL 
for Z-GP-EPI analyses); the heart tissues were 
homogenized in lysis buffer [16]. Then 400μL of 
homogenate were mixed with 40 μL of the 
internal standard DNR (10 µg/mL). These 
samples were treated as the following liquid-
liquid extraction procedure: the samples were 
mixed with 3 mL of the extraction solution 
(methanol : acetonitrile : dichloromethane (1:2:8, 
v/v/v)) and then centrifuged for 15 min at 3000 
rpm and room temperature (25 °C). The 
supernatant was transferred to a clean tube and 
dried by 55 °C nitrogen stream. The residue was 
reconstituted in 100 μL of methanol; 20 μL of the 




To quantify the Z-GP-EPI and EPI concentrations 
in plasma and heart tissue samples, the 
aforementioned HPLC method was validated in 
accordance with the United States Food and 
Drug Administration guidelines for specificity, 
extraction recovery, linearity, intra- and inter-day 
precision and accuracy.  
 
Plasma pharmacokinetic studies 
 
Sprague-Dawley rats were randomly divided into 
4 groups of 5 rats each and treated as follows: 
Group A: 22 µmol/kg EPI; Group B: 11 µmol/kg 
Z-GP-EPI; Group C: 22 µmol/kg Z-GP-EPI; 
Group D: 44 µmol/kg Z-GP-EPI. Rats in Group 
A-D were treated by intravenous injection at a 
dose equivalent to various µmol drugs per 
kilogram body weight. Before 24 h of the 
experiment, jugular vein intubation was 
performed on each rat. In the experiment, blood 
samples (0.5 mL), which were centrifuged for 5 
min at 3000 rpm to obtain plasma samples, were 
drawn from the jugular vein at 0, 0.05, 0.1, 0.17, 
0.34, 0.76, 1, 2, 4, 6, and 8 h after drug 
administration. Simultaneously, an identical 
volume of saline was administered to maintain 
total body fluid balance. Then the blood samples 
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were pretreated as the method mentioned above. 
After determination of EPI and Z-GP-EPI 
concentration, their main pharmacokinetic 
parameters were calculated by pharmacokinetic 
software DAS 3.0. 
 
Drug distribution in the heart  
 
The Bal b/c mice were randomly divided into 2 
groups of 35 mice each and treated as follows: 
Group A’ : 30 µmol/kg EPI and Group B’ : 30 
µmol/kg Z-GP-EPI. Mice of Group A’ and B’ were 
treated by tail intravenous injection at a dose of 
30 µmol EPI or Z-GP-EPI per kilogram body 
weight, which was equivalent to 22 µmol EPI or 
Z-GP-EPI per kilogram weight when 
administered into rats. After intravenous injection 
of EPI or Z-GP-EPI, 5 mice were euthanized for 
each time points at 0.05, 0.167, 0.5, 2, 4, 8, 12 h 
in each group. The heart was removed, washed 
with physiological saline, and blotted onto filter 
papers. Then the heart tissue samples were 
pretreated as the method mentioned above. After 
determination of EPI and Z-GP-EPI 
concentration by HPLC, the comparison of 
concentration between EPI and Z-GP-EPI was 
carried out to describe their different distribution 
in heart tissue.  
 
Statistical analysis  
 
Values are expressed as mean ± standard 
deviation (SD). The data for drug distribution in 
heart were evaluated by one-way ANOVA 
followed by Dunnett Multiple Comparison test 
between different groups. Statistical significance 
of differences was analyzed using SPSS 
software (SPSS for Windows 15.0, SPSS Inc, 




Validation results  
 
Fig 1 and 2 illustrated the representative HPLC 
chromatograms of Z-GP-EPI, EPI, and the 
internal standard DNR in plasma samples and 
heart tissues. The results showed good 
resolution with no interfering peaks among the 
plasma samples and heart tissue of the Z-GP-
EPI, EPI, and DNR (internal standard) groups. 
The extraction recoveries of Z-GP-EPI, EPI, and 
DNR were listed in Tab 1, which indicated that 
they were all more than 85 % at various 
concentrations in plasma and heart tissues. Tab 
2 illustrated the calibration curves of Z-GP-EPI 
and EPI in plasma samples (0.1-100 µg/mL, R2 = 
0.999, 0.01-20 µg/mL, R2 = 0.998) and heart 
tissue (0.5 - 50 µg/mL, R2 = 0.998, 0.5 - 20 
µg/mL, R2 = 0.999). Moreover, the precision and 
accuracy results obtained were presented in Tab 
3. The results showed that RSD % of intra- and 
inter-day precision values were less than 15 % 
(RSD) and method accuracy with recoveries 
were between 85 % - 110 % for the plasma and 
heart samples. The Tab 4 and 5 showed the 
results of stability for Z-GP-EPI or EPI in plasma 
and heart tissues. The results illustrated the 
recoveries were more than 85 % at 4 °C and 90 
% at - 80°C but less than 80 % at 25 °C. 
 
Z-GP-EPI is eliminated more rapidly than EPI 
in plasma  
 
The main pharmacokinetic parameters of Z-GP-
EPI and EPI in plasma were summarized in Tab 
6. As shown, the mean AUC0-∞ of Z-GP-EPI was 
3.93 µg•mL-1•h-1 and the t1/2 was 1.41 h with 
MRT0-∞ of 0.97 h, while the mean AUC0-∞ of EPI 
was 2.84 µg•mL-1•h-1 and the t1/2 was 12.24 h 
with MRT0-∞ of 7.9 h. The CL of Z-GP-EPI was 
6.24 L•kg-1•h-1 with Vd of 5.46 L/kg, while that of 
EPI was 6.18 L•kg-1•h-1 with Vd of 115.48 L/kg. 
 
Z-GP-EPI eliminated more rapidly than EPI in 
heart 
 
Fig 3 illustrates the concentration of Z-GP-EPI 
and EPI in heart tissues at different time after 
intravenous administration of Z-GP-EPI and EPI. 
The results showed that the concentration of Z-
GP-EPI quickly decrease from 17.3 µg/g at 0.05 
h to undetectable concentration at 2 h. However, 
the concentrations of EPI change from 14.3 µg/g 
at 0.05 h to 9.5 µg/g at 2 h. Even at 12h after 





The low cardiotoxicity of Z-GP-EPI was vilified by 
our previous in vivo experiment. However, the 
bioanalytic method of Z-GP-EPI in vivo was still 
unclear. In view of the relationship between 
toxicity and pharmacokinetic, the HPLC method 
for detecting Z-GP-EPI in vivo was established in 
this study. Moreover, the plasma pharmaco-
kinetic and heart distribution of Z-GP-EPI was 
calculated to support the result of low 
cardiotoxicity from in vivo experiment. 
 
According to criteria of United States Food and 
Drug Administration guidelines, a suitable 
bioanalytic method should be specified, linear, 
precise and accurate. The HPLC method 
established in this study show good resolution 
between Z-GP-EPI, EPI and DNR as well as the  
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Figure 1: The representative HPLC chromatograms of Z-GP-EPI, EPI, and the internal standard DNR in plasma 
samples. (A. blank plasma; B. blank plasma spiked with DNR; C. blank plasma spiked with Z-GP-EPI; D. plasma 
sample(taken 1 h after jugular vein administration of Z-GP-EPI) spiked with DNR; E. blank plasma spiked with 




Figure 2: The representative HPLC chromatograms of Z-GP-EPI, EPI, and the internal standard DNR in heart 
tissue samples. (A. blank heart tissue; B. blank heart tissue spiked with DNR; C. blank heart tissue spiked with Z-
GP-EPI; D. heart tissue sample(taken 0.5 h after jugular vein administration of Z-GP-EPI) spiked with DNR; E. 
blank heart tissue spiked with EPI; F. heart tissue sample(12 h after jugular vein administration of EPI) spiked 
with DNR)  
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             Table 1: Extraction recovery of Z-GP-EPI, EPI, and DNR (n = 5) 
 
Variable Administered(µg/mL) Extraction recovery, mean ± SD % Plasma Heart Plasma Heart 
 0.2 0.8 103.62 ± 3.50 85.60 ± 4.24 
Z-GP-EPI 5 5 86.95 ± 0.35 89.78 ± 2.91 
 80 45 106.83 ± 1.15 94.19 ± 2.43 
 0.02 0.8 95.71 ± 0.91 92.61 ± 1.91 
EPI 5 5 85.45 ± 0.29 95.35 ± 2.36 
 15 15 91.89 ± 0.90 105.32 ± 3.60 
DNR 0.8 1 85.65 ± 0.77 87.76 ± 0.57 
             RSD = relative standard deviation 
 
 
               Table 2: Linear regression equations for Z-GP-EPI and EPI (n=7) 
 
Variable  Regression equation R2 Range, µg/mL 
Z-GP-EPI Plasma y = 0.921 x + 0.043 0.999 0.1 - 100 Heart y = 0.731 x – 0.057 0.998 0.5 - 50 
EPI Plasma y = 1.351 x + 0.002 0.998 0.01 - 20 Heart y = 0.492 x – 0.002 0.999 0.5 - 20 
 
 
            Table 3: Precision and accuracy for Z-GP-EPI and EPI (n=5) 
 
Variable  Administered (µg/mL) Precision/RSD % 
Recovery 
(%, mean ± SD) 
   Intra- Inter-  
Plasma 
Z-GP-EPI 
0.2 8.13 12.08 102.68 ± 10.47 
5 5.92 5.49 98.01 ± 1.00 
80 8.74 5.63 93.40 ± 5.32 
EPI 
0.02 6.95 6.41 107.46 ± 0.95 
5 7.71 2.18 111.82 ± 0.72 
15 2.31 5.78 104.53 ± 1.22 
Heart 
Z-GP-EPI 
0.8 7.57 11.67 93.17 ± 0.89 
5 6.41 5.32 98.36 ± 1.54 
45 2.45 3.34 89.76 ± 3.87 
EPI 
0.8 9.59 8.75 88.36 ± 2.67 
5 4.51 6.07 94.62 ± 1.05 
15 8.06 5.54 95.36 ± 0.97 
 
 
Table 4: Stability for Z-GP-EPI and EPI in plasma (n = 5) 
 
Variable Administered (µg/mL) Time 
25 °C/ 
mean ± SD % 
4 °C/  
mean ± SD % 
- 80 °C/ 
mean ± SD % 
Z-GP-EPI 
0.2 12 h or 30 d 32.75 ± 0.22 90.27 ± 0.74 95.17 ± 0.76 (30 d) 24 h or 90 d 25.39 ± 0.46 91.43 ± 0.91 91.84 ± 0.51 (90 d) 
5 12 h or 30 d 40.21 ± 0.42 95.48 ± 0.12 89.43 ± 0.25 (30 d) 24 h or 90 d 31.90 ± 0.48 87.15 ± 0.33 98.52 ± 0.14 (90 d) 
80 12 h or 30 d 52.94 ± 0.64 112.68 ± 0.92 103.58 ± 0.79 (30 d) 24 h or 90 d 42.63 ± 0.77 83.25 ± 1.27 88.79 ± 0.47 (90 d) 
EPI 
0.02 12 h or 30 d 53.49 ± 0.32 100.61 ± 0.21 93.48 ± 1.01 (30 d) 24 h or 90 d 23.38 ± 0.57 93.43 ± 0.63 93.69 ± 2.07 (90 d) 
1 12 h or 30 d 64.99 ± 1.01 80.94 ± 0.32 93.69 ± 0.98 (30 d) 24 h or 90 d 41.98 ± 0.99 81.38 ± 0.55 91.74 ± 0.70 (90 d) 
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Table 5: Stability for Z-GP-EPI and EPI in heart (n = 5) 
 
Variable Administered (µg/mL) Time 
25 °C/  
(%, mean±SD) 
4 °C/  
(%, mean±SD) 
– 80 °C/ 
(%, mean±SD) 
Z-GP-EPI 0.8 12 h or 30 d 25.13 ± 0.79 89.55 ± 2.04 94.33 ± 0.46 (30 d) 
 
24 h or 90 d 21.37 ± 0.62 85.43 ± 1.09 92.59 ± 0.31 (90 d) 
5 12 h or 30 d 41.39 ± 0.73 93.05 ± 1.11 87.22 ± 0.98 (30 d) 24 h or 90 d 37.11 ± 0.92 86.33 ± 0.33 97.44 ± 0.73 (90 d) 
45 12 h or 30 d 26.41 ± 0.72 105.68 ± 1.86 101.39 ± 1.91 (30 d) 24 h or 90 d 21.64 ± 0.86 93.14 ± 2.75 95.62 ± 0.81 (90 d) 
EPI 0.8 12 h or 30 d 49.55 ± 0.13 104.54 ± 0.77 95.38 ± 0.51 (30 d) 
 
24 h or 90 d 31.89 ± 0.08 90.80 ± 0.46 93.11 ± 0.43 (90 d) 
5 12 h or 30 d 70.65 ± 0.09 86.32 ± 1.01 98.72 ± 1.18 (30 d) 24 h or 90 d 50.77 ± 2.06 84.24 ± 1.03 90.51 ± 0.95 (90 d) 
15 12 h or 30 d 73.21 ± 0.55 89.62 ± 0.51 91.74 ± 1.02 (30 d) 24 h or 90 d 51.44 ± 0.69 86.02 ± 0.93 105.20 ± 1.49 (90 d) 
 
           Table 6: Plasma pharmacokinetic parameters for Z-GP-EPI and EPI  
 
Parameter Z-GP-EPI (mean ± SD)* EPI (mean ± SD)* 
AUC0-8 (µg·mL-1·h-1) 3.90 ± 1.97 2.43 ± 0.30 
AUC0-∞ (µg·mL-1·h-1) 3.93 ± 2.17 2.84 ± 0.44 
MRT0-8 (h) 0.74 ± 0.21 1.77 ± 0.30 
MRT0-∞ (h) 0.97 ± 0.52 7.90 ± 1.58 
CL (L·kg-1·h-1) 6.24 ± 1.56 6.18 ± 1.68 
Vd (L/kg) 5.46 ± 2.80 115.48 ± 11.43 
t1/2 (h) 1.41 ± 0.53 12.24 ± 2.57 
*22 µmol/kg dose; AUC = area under the concentration-time curve; CL = clearance; MRT = mean residence time; 
t1/2 = terminal elimination half-life; Vd = apparent volume of distribution 
 
 
Figure 3: Concentrations of Z-GP-EPI and EPI in heart tissues after intravenous administration (*:P < 0.05 vs. 
EPI). A: The mice in this group were injected with Z-GP-EPI (30 µmol/kg). B: The mice in this group were injected 
with EPI (30 µmol/kg) 
 
linear correlation between concentration and 
peak area at range 0.01 - 20 µg/mL in plasma 
and 0.5 - 20 µg/mL in heart tissue for EPI, 0.1 - 
100 µg/mL in plasma and 0.5 - 50 µg/mL in heart 
tissue for Z-GP-EPI, respectively. Meanwhile, 
intra- and inter-day precision, extraction recovery 
and accuracy are all match the criteria. Thus the 
bioanalytic method was considered to be a 
feasible method to determine content of Z-GP-
EPI and EPI in plasma and heart tissues. Then 
the stability of Z-GP-EPI and EPI were also 
evaluated by the established method in this 
study, result claimed that Z-GP-EPI and EPI 
were not stable at room temperature for the 
mean recoveries from the nominal 
concentrations declined to less than 80 %. This 
indicates that the plasma and heart samples 
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should be stored in 4 °C or - 80 °C immediately 
after collection. 
 
After confirmation of the bioanalytic method of Z-
GP-EPI and EPI, the plasma pharmacokinetic of 
Z-GP-EPI and EPI were calculated and 
compared. No significant difference was 
observed in AUC and CL between Z-GP-EPI and 
EPI. Smaller MRT0-∞, t1/2 and Vd of Z-GP-EPI 
suggest that it might be distributed into 
organization faster or a quicker elimination 
process. Then we further determined the heart 
distribution of Z-GP-EPI and EPI, the result show 
Z-GP-EPI obviously eliminate more quickly than 
EPI in heart tissues. Z-GP-EPI could not be 
detected at even 2 h after administration. 
Meanwhile, we didn’t detect free EPI 
enzymolysised from Z-GP-EPI in heart tissues at 
2 h. However, EPI could still be detected at 12 h 
after administration of EPI (30 µmol/kg). The 
difference of elimination between Z-GP-EPI and 
EPI in heart tissues might support the low 
cardiotoxicity of Z-GP-EPI concluded from our 
previous in vivo studies. Next stage, PBPK 
model of Z-GP-EPI would be constructed for 
plasma and main organizations to clearly 




The results obtained in this work are noteworthy 
as they indicate that the developed HPLC assay 
method for Z-GP-EPI and EPI is feasible. The 
results also demonstrate that the cardiotoxicity of 
Z-GP-EPI is lower than that of EPI. These 
findings provide a basis for the future study of Z-





This work was financially supported by grants 
from National Natural Science Foundation of 
China (nos. 30973565, 81273538, and 
81202461), National Important Technology 
Project “Creation of Major New Drugs” (no. 
2009ZX09103 - 040) and China Postdoctoral 




1. Hortobagyi, G. Anthracyclines in the treatment of cancer. 
Drugs 1997; 54: 1-7. 
2. Lenaz L, Page JA. Cardiotoxicity of adriamycin and 
related anthracyclines. Cancer Treat Rev 1976; 3(3): 
111. 
3. Devalapally H, Rajan KS, Akkinepally RR, Devarakonda 
RK. Safety pharmacokinetics and biodistribution 
studies of a β-galactoside prodrug of doxorubicin for 
improvement of tumor selective chemotherapy. Drug 
Dev Ind Pharm 2008; 34: 789-795. 
4. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. 
Anthracyclines: molecular advances and 
pharmacologic developments in antitumor activity and 
cardiotoxicity. Pharmacol Rev 2004; 56(2): 185-229.  
5. Danesi R, Fogli S, Gennari A, Conte P, Tacca MD. 
Pharmacokinetic-pharmacodynamic relationships of 
the anthracycline anticancer drugs. Clin 
Pharmacokinet 2002: 41(6): 431-444.  
6. Rivera E. Liposomal anthracyclines in metastatic breast 
cancer: Clinical update. Oncologist 2003; 8: 3-9. 
7. Chen WT, Kelly T. Seprase complexes in cellular 
invasiveness. Cancer Metast Rev 2003; 22: 259-269. 
8. Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins 
W, Divgi CR, Hanson LH, Mitchell P, Gansen DN, et 
al. A Phase I dose-escalation study of sibrotuzumab 
in patients with advanced or metastatic fibroblast 
activation protein-positive cancer. Clin Cancer Res 
2003; 9(5): 1639-1647. 
9. Lee J, Fassnacht M, Nair S, Boczkowski D, Gilboa E. 
Tumor immunotherapy targeting fibroblast activation 
protein, a product expressed in tumor-associated 
fibroblasts. Cancer Res 2005; 65(23): 11156-11163. 
10. Loeffler M, Krüger JA, Niethammer AG, Reisfeld RA. 
Targeting tumor-associated fibroblasts improves 
cancer chemotherapy by increasing intratumoral drug 
uptake. J Clin Invest 2009 Feb; 119(2): 421-421. 
11. Delacher S, Derendorf H, Hollenstein U, Brunner M, 
Joukhadar C, Hofmann S, Georgopoulos A, Eichler 
HG, Muller M. A combined in vivo pharmacokinetic-in 
vitro pharmacodynamic approach to simulate target 
site pharmacodynamics of antibiotics in humans. J 
Antimicrob Chemother 2000; 46: 733-739. 
12. Ikawa K, Morikawa N, Ohge H, Ikeda K, Sueda T, 
Taniwaki M, Kurisu K. Pharmacokinetic-
pharmacodynamic target attainment analysis of 
meropenem in Japanese adult patients. J Infect 
Chemother 2010; 16: 25-32. 
13. Fielding RM, Singer AW, Wang LH, Babbar S, Guo LS. 
Relationship of pharmacokinetics and drug 
distribution in tissue to increased safety of 
amphotericin B colloidal dispersion in dogs. 
Antimicrob Agents Chemother 1992; 36: 299-307. 
14. Jones G. Pharmacokinetics of vitamin D toxicity. Am J 
Clin Nutr 2008; 88: 582S-586S. 
15. National Institute of Health, USA. Public health service 
policy on humane care and use of laboratory animals; 
2002. 
16. Gao F, Li L, Zhang H, Yang W, Chen H, Zhou J, Zhou Z, 
Wang Y, Cai Y, Li X..Deoxycholic acid modified-
carboxymethyl curdlan conjugate as a novel carrier of 
epirubicin: In vitro and in vivo studies. Int J Pharm 
2010; 392: 254-260. 
 
